Skip to content

The latest company news, press releases, and resources about Servier and everything our company has to offer.

Advanced Search
  • servier logo
     
    11.12.2024
    Servier to Present Data on IDH-mutant Glioma at the 2024 Society for Neuro-Oncology (SNO) Congress
  • servier logo
     
    08.06.2024
    Servier's VORANIGO® (vorasidenib) Tablets Receives FDA Approval as First Targeted Therapy for Grade 2 IDH-mutant Glioma
  • servier logo
     
    05.30.2024
    Servier Initiates Critical Dialogue on AYA Cancer Survivorship at ASCO 2024
  • servier logo
     
    05.23.2024
    Servier Highlights Commitment to Improving Cancer Outcomes at ASCO 2024
  • servier logo
     
    05.14.2024
    Servier Ranks 1st Across Several Categories in 2023-2024 PatientView U.S. Corporate Reputation Survey
Show 5102550100 per page
Media Contacts

Servier Media Relations
us2mediarelations@servier.com

Subscribe